COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
NCT02404376 on ClinicalTrials.gov · last registry update 2020-11-03
Finished August 2019, after enrolling 378 people. Primary outcome, as filed: Myocardial Infarct Size. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Sponsor type
- Other
- Enrollment
- 378
- Started
- 2016-03
- Primary completion
- 2019-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Myocardial Infarct Size
Conditions studied
ST Elevation Acute Myocardial Infarction
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.